Abemaciclib + Nonsteroidal Aromatase Inhibitor (NSAI)
ApprovedWithdrawn 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Metastatic Breast Cancer
Conditions
Metastatic Breast Cancer
Trial Timeline
Sep 16, 2019 → Mar 23, 2023
NCT ID
NCT03988114About Abemaciclib + Nonsteroidal Aromatase Inhibitor (NSAI)
Abemaciclib + Nonsteroidal Aromatase Inhibitor (NSAI) is a approved stage product being developed by Eli Lilly for Metastatic Breast Cancer. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT03988114. Target conditions include Metastatic Breast Cancer.
What happened to similar drugs?
20 of 20 similar drugs in Metastatic Breast Cancer were approved
Approved (20) Terminated (7) Active (0)
Hype Score Breakdown
Clinical
20
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03988114 | Approved | Withdrawn |
Competing Products
20 competing products in Metastatic Breast Cancer